Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Rosacea Erythema Telangiectasia
NCT06282679Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of botulinum toxin type A in rosacea, sponsored by Nanjing First Hospital. Primary endpoint: Clinical Erythema Assessment at 12 weeks. Started Apr 2022; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT06282679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282679.